Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

1.

Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.

Lew MF, Somogyi M, McCague K, Welsh M; Lce QoL Study Group.

Int J Neurosci. 2011 Nov;121(11):605-13. doi: 10.3109/00207454.2011.598982. Epub 2011 Aug 16.

PMID:
21843110
[PubMed - indexed for MEDLINE]
2.

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Eggert K, Skogar O, Amar K, Luotonen L, Kuoppamäki M, Leinonen M, Nissinen H, Oertel W.

J Neural Transm. 2010 Mar;117(3):333-42. doi: 10.1007/s00702-009-0344-4. Epub 2009 Dec 15.

PMID:
20013007
[PubMed - indexed for MEDLINE]
3.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
[PubMed - indexed for MEDLINE]
4.

Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.

Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I; F-01 Study Group.

Eur Neurol. 2001;45(2):111-8.

PMID:
11244274
[PubMed - indexed for MEDLINE]
5.

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K; ComQol Study Group.

Acta Neurol Scand. 2005 Jan;111(1):21-8.

PMID:
15595934
[PubMed - indexed for MEDLINE]
6.

Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.

Delea TE, Thomas SK, Hagiwara M, Mancione L.

Curr Med Res Opin. 2010 Jul;26(7):1543-52. doi: 10.1185/03007991003780628.

PMID:
20429819
[PubMed - indexed for MEDLINE]
7.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
[PubMed - indexed for MEDLINE]
8.

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group.

Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343.

PMID:
19058133
[PubMed - indexed for MEDLINE]
9.

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.

Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D.

J Neural Transm. 2005 Feb;112(2):221-30. Epub 2004 Oct 22.

PMID:
15503197
[PubMed - indexed for MEDLINE]
10.

Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.

Gershanik O, Emre M, Bernhard G, Sauer D.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):963-71.

PMID:
14499313
[PubMed - indexed for MEDLINE]
11.

[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].

Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(1):51-4. Russian.

PMID:
19156087
[PubMed - indexed for MEDLINE]
12.

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.

Grandas F, Hernández B; PRACTICOMT Study Group.

Eur J Neurol. 2007 Mar;14(3):282-9.

PMID:
17355548
[PubMed - indexed for MEDLINE]
13.

Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.

Lyons KE, Pahwa R.

Clin Neuropharmacol. 2006 Mar-Apr;29(2):73-6.

PMID:
16614538
[PubMed - indexed for MEDLINE]
14.

Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.

Tolosa E, Hernández B, Linazasoro G, López-Lozano JJ, Mir P, Marey J, Kulisevsky J.

J Neural Transm. 2014 Apr;121(4):357-66. doi: 10.1007/s00702-013-1114-x. Epub 2013 Nov 20.

PMID:
24253234
[PubMed - indexed for MEDLINE]
15.

Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.

Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.

Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:41-9.

PMID:
15496222
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.

Onofrj M, Thomas A, Vingerhoets F, Martin W, Giménez-Roldán S, Azulay JP, Bernhard G, Schmidt W, Markabi S.

J Neural Transm. 2004 Aug;111(8):1053-63. Epub 2004 May 12.

PMID:
15254793
[PubMed - indexed for MEDLINE]
17.

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, Ellmén J.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):756-60.

PMID:
20979935
[PubMed - indexed for MEDLINE]
18.

[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.

Neurologia. 2005 May;20(4):180-8. Review. Spanish.

PMID:
15891947
[PubMed - indexed for MEDLINE]
19.

Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.

Reichmann H, Emre M.

Expert Rev Neurother. 2012 Feb;12(2):119-31. doi: 10.1586/ern.11.203. Review. Erratum in: Expert Rev Neurother. 2012 May;12(5):628.

PMID:
22288667
[PubMed - indexed for MEDLINE]
20.

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group.

Lancet. 2005 Mar 12-18;365(9463):947-54.

PMID:
15766996
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk